Published in Arch Neurol on April 01, 2006
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol (2008) 3.92
Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression. J Am Stat Assoc (2007) 1.18
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol (2006) 1.05
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry (2007) 1.02
Treatment selection and experience in multiple sclerosis: survey of neurologists. Patient Prefer Adherence (2014) 0.89
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases (2015) 0.88
Early multiple sclerosis: to treat or not to treat? Arch Neurol (2006) 0.80
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
Multiple sclerosis therapy: an update on recently finished trials. J Neurol (2007) 0.78
Proteomic strategies in multiple sclerosis and its animal models. Proteomics Clin Appl (2007) 0.76
Conversion from radiologically isolated syndrome to multiple sclerosis. Int J Prev Med (2014) 0.75
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol (2006) 4.25
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Citation and readership metrics: how does Neurology measure up? Neurology (2008) 2.61
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Arch Neurol (2004) 2.37
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc (2004) 2.29
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
Demyelination versus remyelination in progressive multiple sclerosis. Brain (2010) 1.82
Multiple sclerosis. Annu Rev Med (2002) 1.80
An approach to the diagnosis of acute transverse myelitis. Semin Neurol (2008) 1.80
Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol (2008) 1.72
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
XopD SUMO protease affects host transcription, promotes pathogen growth, and delays symptom development in xanthomonas-infected tomato leaves. Plant Cell (2008) 1.62
p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies. Pathology (2005) 1.62
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60
Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol (2005) 1.60
Pathology of demyelinating diseases. Annu Rev Pathol (2012) 1.52
Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol (2005) 1.51
Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. Neurology (2012) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol (2007) 1.49
A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol (2006) 1.43
The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler (2011) 1.42
Gynaecology meets neurology: paraneoplastic cerebellar degeneration. Aust N Z J Obstet Gynaecol (2005) 1.40
The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 1.40
Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol (2012) 1.40
Gonadoblastoma progressing to dysgerminoma in a 55-year-old woman with normal karyotype. Pathology (2007) 1.39
Neuromyelitis optica: changing concepts. J Neuroimmunol (2007) 1.39
Bright red nuclei. Neurology (2004) 1.38
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol (2004) 1.36
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist (2009) 1.29
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis (2004) 1.28
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol (2012) 1.27
Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis (2006) 1.26
Retracted Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res (2004) 1.26
Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer (2013) 1.25
Clearance of Theiler's virus infection depends on the ability to generate a CD8+ T cell response against a single immunodominant viral peptide. Eur J Immunol (2003) 1.25
Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol (2007) 1.24